A pivotal moment in the fight to end AIDS -- ensuring lifesaving innovation reaches those who need it most, wherever they live ...

When an HIV Scientific Breakthrough Isn’t Enough Trump administration funding cuts and dismantling of USAID force the focus to shift from elimination back to treatment.

The UNAIDS annual report warns that Trump era HIV funding cuts could lead to 6 million more infections and 4 million deaths ...

A landmark breakthrough in HIV prevention — a scientific feat decades in the making — received final approval from the Food and Drug Administration last month. Gilead Sciences’ lenacapavir is ...

Lower-income countries, including South Africa, gain unprecedented access to lenacapavir, a revolutionary HIV prevention drug ...

HIV jab has signed a deal to supply the costly injection at a knock-down price to as many as two million people in poorer countries.

A new report says the withdrawal of U.S. funding has caused a “systemic shock” to the global effort against AIDS and HIV.

Gilead has partnered with Global Fund to supply lenacapavir for the prevention of HIV as pre-exposure prophylaxis (PrEP).

The first lenacapavir jabs will be delivered later this year under a new agreement between Gilead Sciences and the Global Fund ...

The breakthrough of Abivax’s study results is that their HIV treatment could potentially remove the virus completely, induce long term control of the viral load and even prevent the emergence of ...